Clinical Trials Paving the Way for Improved Vulvar Cancer Treatment

Share

Cancers of the vulva – the external portion of the female genitals – are diagnosed in approximately 4,700 women in the United States each year. While many patients can be cured by a combination of surgery, chemotherapy, and radiation therapy, others – particularly those whose cancer has metastasized to other parts of the body – often don’t fare as well.

As one of the rarer forms of gynecologic cancer, vulvar cancer hasn’t attracted as much research funding as other forms. Still, several efforts are under way to make treatment options more effective, according to Neil Horowitz, MD, a vulvar cancer expert at the Susan F. Smith Center for Women’s Cancers at Dana-Farber.

Neil Horowitz, MD

Neil Horowitz, MD

One clinical trial is studying the effectiveness of chemotherapy administered at the same time as radiation therapy for women with extensive tumors confined to the vulva. The size of such tumors and proximity to the urethra (the tube that carries urine from the bladder), clitoris, or anus often means that surgeons would have to remove these important structures to remove the cancer. The new treatment seeks to shrink the tumor prior to surgery, reducing the long-term consequences of surgery or perhaps avoiding surgery altogether. Patients are treated with the chemotherapy agents cisplatin and gemcitabine, along with intensity-modified radiation therapy (IMRT), which uses computer-generated 3-D images to show the size and shape of the tumor. Previous trials have shown the effectiveness of cisplatin and traditional radiation therapy; the new trial is exploring whether the addition of gemcitabine and the use of IMRT offers even better results.

Another trial is confirming the safety and effectiveness of omitting a full lymph node evaluation after using a less-invasive method of determining whether vulvar cancer has metastasized, or spread. The conventional approach is to remove many of the lymph nodes near the diseased vulva and examine them for the presence of vulvar cancer cells – a procedure that can lead to a painful buildup of lymph fluid and swelling of the lower extremities. The trial is analyzing whether removing only the main, or “sentinel,” lymph nodes can be just as effective for detecting metastasis while producing less swelling. Additionally, the trial seeks to determine if radiation therapy rather than a complete lymph node removal can be used if a positive sentinel lymph node is discovered.

Horowtiz and his Dana-Farber colleague Ursula Matulonis, MD, medical director of Gynecologic Oncology at the Susan F. Smith Center, recently completed a clinical trial that found that the drug Tarceva temporarily stalled or reversed the growth of squamous cell vulvar cancers in some women. The trial marked the first time a “targeted” therapy, which aims at a specific abnormal protein in cancer cells, has been tested in patients with vulvar cancer.

3 Comments:

  1. Dr. Horowitz is an exceptional doctor. He was so very good with my mother in 2011. She asked him often ” What would you do if it was your mom?” He walked her through her journey with compassion and strength when we could not find ours. I am very sad that she lost her battle but am glad to hear the Tarceva trial she was on is making progress to help others.

  2. This is the first time I have received a Dana Farber E-mail as a patient having had Vulvar cancer surgery this past July 2013…..I can’t tell you how much I need some type of help/communication with all that happened to me when the cancer was found. I was very fortunate to have a most capable and compassionate surgeon, Dr. Ross Berkowitz.
    My outlook is fairly good….the ONE to ONE program was not as helpful although one lovely lady was found in TN who I could call, I did and we had a couple of talks about my recovery. I could have used so much more but with a rare cancer like Vulvar, you just don’t have the same as you would with breast cancer, I guess. One day at a time….it’s what we all have I guess. Just reading the article on treatment for this was most informative.
    I needed all the help I could get, unfortunately it just wasn’t all I hoped it would be.

    • Dear Mary –

      I am sorry to hear about the trouble you had finding support. I would recommend checking out our patient and family support site as well as information about our social work program.

      In addition, the CancerConnect online community is a great resource for patients to join online conversations with other patients about living with cancer, or life after treatment. You can safely express your thoughts, pose questions, voice concerns, or just read what others have to say.

      I hope these resources are helpful and wish you all the best.

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image
Refresh

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>